Emerson Electric Co【EMR】株式ニュース

AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost AdvantagesApril 9, 2026 9:00 AM
InvestorsHub NewsWireAI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost AdvantagesAINewsWire Editorial Coverage: As regulatory demands intensify and production environments become more complex, pharmaceutical manufacturers are shifting beyond traditional quality assurance systems toward a new operational model: integrating artificial intelligence directly into manufacturing workflows as a continuous compliance layer. Rather than depending on retrospective audits and manual checks, AI-driven technologies are now capable of monitoring, validating and optimizing production processes in real time to ensure alignment with evolving Good Manufacturing Practice ("GMP") requirements. This transformation is becoming increasingly visible across the sector and aligns with companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), which operate at the intersection of biotechnology and advanced digital systems, reflecting a broader transition toward intelligent, automated compliance infrastructures. Through its focus on AI, Oncotelic sits alongside other innovation-driven organizations including Rockwell Automation Inc. (NYSE: ROK), Emerson Electric Co. (NYSE: EMR), Thermo Fisher Scientific Inc. (NYSE: TMO) and Danaher Corp. (NYSE: DHR), all of which are contributing to this evolving technological landscape.Increasingly, manufacturers are adopting AI-powered continuous monitoring systems that evaluate compliance dynamically throughout the production process rather than after completion.Regulatory bodies around the world are placing increasing emphasis on data integrity, traceability and minimizing human error. The idea of Pharma 4.0 characterizes a significant evolution in pharmaceutical development and manufacturing.Current obstacles underscore the demand for increasingly dependable data-driven systems, with AI-enabled automation paving the way for reduced variability, enhanced consistency and decreased costly disruptions.A more significant change is underway as artificial intelligence, robotics and biotechnology come together to reshape pharmaceutical infrastructure. Click here to view the custom infographic of the Oncotelic Therapeutics editorial.Embedded Intelligence Enables Continuous ComplianceHistorically, pharmaceutical manufacturing relied heavily on batch-based testing and manual recordkeeping to verify compliance. While these methods were sufficient in earlier production models, they often introduce delays and create opportunities for human error. Increasingly, manufacturers are adopting AI-powered continuous monitoring systems that evaluate compliance dynamically throughout the production process rather than after completion.This shift supports initiatives from the U.S. Food and Drug Administration ("FDA"), which has encouraged the adoption of advanced manufacturing technologies and continuous production models. Programs such as the FDA's Emerging Technology Program and Advanced Manufacturing Technologies initiative promote the use of innovative systems designed to enhance reliability, improve product quality and minimize the risk of manufacturing failures or supply disruptions. These efforts highlight a transition from reactive oversight to proactive compliance strategies.AI technologies facilitate this transformation by regularly evaluating streams of production data, including variables such as temperature, pressure and material uniformity, to identify anomalies as they occur. Rather than detecting issues during post-production reviews, these systems enable immediate intervention, helping maintain product integrity. This ability supports real-time release testing, a model in which products are evaluated and approved based on live process data instead of delayed laboratory testing.As this approach gains adoption, companies such as Oncotelic Therapeutics are part of a broader ecosystem that increasingly views embedded intelligence as a core component of compliance. Their alignment with AI-enabled platforms reflects a growing understanding that compliance is no longer a discrete checkpoint, but an integrated function operating continuously across the manufacturing lifecycle.Heightened Regulation Accelerates Automation AdoptionRegulatory bodies around the world are placing increasing emphasis on data integrity, traceability and minimizing human error. The European Medicines Agency has released detailed guidance on computerized systems and data management, stressing the importance of secure, attributable and contemporaneous records. Likewise, FDA expectations reinforce following ALCOA+ principles, which ensure that data is attributable, legible, contemporaneous, original and accurate.These rising standards are hastening the move toward automation. Manual processes, which have long been standard across pharmaceutical manufacturing, are now seen as potential sources of variability and documentation risk. According to the International Society for Pharmaceutical Engineering, digital transformation initiatives are becoming essential to improving compliance outcomes and reducing operational risk in modern pharmaceutical systems.AI-enhanced automation provides a solution by standardizing workflows and ensuring consistent data capture. These systems automatically generate audit-ready documentation, reducing reliance on human input while improving transparency and accuracy. In sterile manufacturing environments, where contamination risks must be minimized, automation also reduces human involvement, thereby reinforcing compliance outcomes.Within this regulatory environment, Oncotelic Therapeutics represents a wider strategic alignment with innovation driven by compliance requirements. As pharmaceutical companies increasingly prioritize automation and data integrity, organizations leveraging AI-enabled platforms are better positioned to meet evolving regulatory expectations.Pharma 4.0 Drives Intelligent Production EcosystemsThe idea of Pharma 4.0 characterizes a significant evolution in pharmaceutical development and manufacturing. Sparked by Industry 4.0, this model integrates digital technologies such as artificial intelligence, robotics and advanced analytics into interconnected production systems. Research indicates that these technologies are transforming biopharma operations by increasing productivity, improving product quality and supporting more agile, data-driven decision-making across the value chain.In such environments, manufacturing systems are fully connected, enabling data to move between equipment, quality systems and supply chain processes. AI-driven analytics use this data to optimize performance, anticipate maintenance needs and ensure compliance. This integration enhances traceability, enabling manufacturers to monitor every stage of production with greater precision.Large pharmaceutical companies are now employing these capabilities. Pfizer Inc. has implemented digital manufacturing programs that leverage AI and data-driven systems to improve efficiency and operational performance. Johnson & Johnson has invested in AI-powered platforms to enhance decision-making and streamline development processes, while Novartis AG is using machine learning and advanced analytics to build intelligent manufacturing systems and integrate AI across production environments. These initiatives demonstrate a broader industry commitment to adopting intelligent manufacturing as a pathway to improved compliance and operational efficiency.Within this context, Oncotelic Therapeutics represents a growing class of entities operating at the intersection of biotechnology and digital innovation. As Pharma 4.0 adoption increases, organizations supporting AI-enabled systems are increasingly positioned to participate in scalable, data-driven manufacturing ecosystems.Efficiency Gains Reduce Cost, RiskThe process of bringing a new pharmaceutical product to market remains both time-consuming and expensive, often requiring more than a decade of development and substantial financial investment. A substantial part of these expenses are caused by high failure rates, increasing process complexity and inefficiencies across development and manufacturing stages. These obstacles underscore the demand for increasingly dependable data-driven systems, with AI-enabled automation paving the way for reduced variability, enhanced consistency and decreased costly disruptions.Deloitte has noted that digital transformation in life sciences manufacturing can boost operational efficiency by streamlining processes, increasing productivity and reducing errors. AI systems can evaluate both real-time and historical data to anticipate possible problems, allowing manufacturers to intervene before issues escalate.Continuous manufacturing, frequently supported by AI and advanced process control technologies, further improves efficiency by reducing reliance on large-batch production. Instead, it enables continuous processing with real-time monitoring, lowering inventory requirements and accelerating time-to-market. The FDA has actively supported this approach, recognizing its ability to improve product quality, reduce costs and provide a more flexible alternative to traditional batch manufacturing.The combination of reduced risk and improved efficiency creates a compelling value proposition for companies operating at the intersection of AI and biotechnology. In this environment, organizations such as Oncotelic Therapeutics reflect the growing importance of platforms capable of supporting intelligent automation and compliance as the industry seeks to manage costs more effectively.AI, Robotics Reshape Biotech InfrastructureA more significant change is underway as artificial intelligence, robotics and biotechnology come together to reshape pharmaceutical infrastructure. Modern manufacturing facilities increasingly rely on robotic systems to automate complex processes such as aseptic filling, material handling and inspection, decreasing the need for human intervention while improving precision and efficiency. In addition, AI-driven systems monitor operations in real time, analyzing data to detect irregularities and optimize performance, supporting continuous compliance.This meeting of technology is especially significant in sterile manufacturing environments, where minimizing human involvement is essential to reducing contamination risk. Robotics provide precision and consistency, while AI systems continuously monitor environmental conditions and process variables. These technologies come together to make integrated systems that sustain both compliance and operational quality.Market data highlights the reach of this transformation. The global pharmaceutical manufacturing sector, already valued in the hundreds of billions of dollars, is expected to reach $1 trillion in the coming years. Investment is increasingly directed toward automation, digital infrastructure and AI-enabled production systems designed to improve efficiency and regulatory compliance. This trend indicates a broader reallocation of capital toward technologies that enhance scalability, precision and operational control.As this movement continues to climb upward, companies aligned with AI-driven platforms may benefit from sustained growth and improved margins. Positioned within this evolving landscape, Oncotelic Therapeutics represents the type of organization that could participate in this transformation, where intelligent automation and integrated compliance redefine pharmaceutical manufacturing.AI and Robotics Drive Next Phase of TransformationArtificial intelligence and robotics are rapidly reshaping industrial operations, enabling companies to improve efficiency, reduce manual intervention and unlock new levels of productivity. Across manufacturing, infrastructure and life sciences, organizations are increasingly deploying intelligent automation systems that combine real-time data, machine learning and advanced robotics to streamline workflows and support decision-making.Rockwell Automation Inc. (NYSE: ROK) announced a major step in real-time intelligence for industrial teams. The company introduced its integration of NVIDIA Nemotron Nano, a purpose-built small language model ("SLM") optimized for FactoryTalk(R) Design Studio(TM) and other Rockwell product workflows. In collaboration with NVIDIA, Rockwell is leveraging the open-source Nemotron-Nano-9B-v2 model and NVIDIA NeMo to deliver an edge-based generative AI capability designed specifically for industrial environments.Emerson Electric Co. (NYSE: EMR) has introduced a new AI-powered environment to enhance upstream lifecycle decision making. Emerson's AspenTech Subsurface Intelligence(TM) ("ASI") is an open, cloud-native agentic environment that incorporates AI to transform the user experience and accelerate subsurface-related decision making while leveraging existing investments in legacy applications. ASI fulfills a critical industry need to work in an agile, multidisciplinary manner, optimize production and improve access to information trapped throughout various parts of the organization.Thermo Fisher Scientific Inc. (NYSE: TMO) integrates AI and robotics into laboratory and semiconductor environments with its Thermo Scientific Vulcan(TM) Automated Lab. The platform is designed to drive a new era of process development and control in semiconductor manufacturing. The seamlessly integrated system enhances productivity, increases yield and reduces operating costs for semiconductor manufacturers.Danaher Corp. (NYSE: DHR) announced a collaboration designed to enhance life science lab connectivity by integrating automated imaging and detection systems into research workflows. Molecular Devices, LLC., a leading provider of high-performance life science solutions and an operating company of Danaher is partnering with Automata, a London-based lab automation company developing fully integrated, AI-ready platforms for life science researchers. As labs face mounting pressure to boost throughput and data quality while managing limited hands-on resources, new integrations between Molecular Devices' imaging and detection systems and Automata's LINQ platform will provide a scalable, interoperable foundation for fully connected research workflows.These developments reflect a broader transformation across industrial and scientific sectors, where AI and robotics are becoming foundational technologies rather than experimental tools. As companies continue to integrate intelligent systems into core operations, these advancements highlight the growing importance of automation in driving efficiency, scalability and long-term competitiveness across the global economy.For more information, visit Oncotelic Therapeutics Inc.
Original: AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages

Emerson Reports First Quarter 2026 Results; Updates 2026 OutlookFebruary 3, 2026 4:05 PM
PR Newswire (US)

ST. LOUIS, Feb. 3, 2026 /PRNewswire/ -- Emerson (NYSE: EMR) today reported results for its first quarter ended December 31, 2025 and updated its full year outlook for fiscal 2026. Emerson also declared a quarterly cash dividend of $0.555 per share of common stock payable March 10, 2026 to stockholders of record on February 13, 2026.

(dollars in millions, except per share)2025 Q12026 Q1ChangeUnderlying Orders1

9 %Net Sales$4,175$4,3464 %Underlying Sales2

2 %Pretax Earnings$775$775
Margin18.6 %17.8 %(80) bpsAdjusted Segment EBITA3$1,169$1,203
Margin28.0 %27.7 %(30) bpsGAAP Earnings Per Share$1.02$1.075 %Adjusted Earnings Per Share4$1.38$1.466 %Operating Cash Flow$777$699(10) %Free Cash Flow$694$602(13) %Management Commentary"Emerson met sales commitments and exceeded expectations for profitability as our global teams continue to execute well," said Emerson President and Chief Executive Officer Lal Karsanbhai. "We delivered a fourth consecutive quarter of strong underlying orders growth, and we are experiencing robust demand for our automation technology, led by Software & Systems, with strength in North America, India and the Middle East & Africa."Karsanbhai continued, "Emerson is accelerating innovation, introducing new products and delivering on the critical programs we highlighted at our 2025 investor conference. These releases advance our capabilities in software-defined automation and further enhance our leadership position in high-growth verticals."2026 OutlookThe following tables summarize the fiscal year 2026 guidance framework. As we pivot capital allocation to returning cash to shareholders, the 2026 outlook assumes returning ~$2.2B through ~$1B share repurchases and ~$1.2B of dividends.
2026 Q22026Net Sales Growth3% - 4%~5.5%Underlying Sales Growth1% - 2%~4%Earnings Per Share$1.06 - $1.11$4.78 - $4.93Amortization of intangibles~$0.35~$1.38Restructuring and related costs~$0.06~$0.14Acquisition/divestiture fees and related costs~$0.02~$0.06Discrete taxes~$0.01~$0.04Adjusted Earnings Per Share$1.50 - $1.55$6.40 - $6.55Operating Cash Flow
$4.0B - $4.1BFree Cash Flow
$3.5B - $3.6BShare Repurchase
~$1.0B1 Underlying orders do not include AspenTech.2 Underlying sales exclude the impact of currency translation, and significant acquisitions and divestitures.3 Adjusted segment EBITA represents segment earnings less restructuring and intangibles amortization expense.4 Adjusted EPS excludes intangibles amortization expense, restructuring and related costs, acquisition/divestiture gains, losses, fees and related costs, and discrete taxes.Conference CallToday, beginning at 3:30 p.m. Central Time / 4:30 p.m. Eastern Time, Emerson management will discuss the first quarter results during an investor conference call. Participants can access a live webcast available at https://ir.emerson.com at the time of the call. A replay of the call will be available for 90 days. Conference call slides will be posted in advance of the call on the company website.About EmersonEmerson (NYSE: EMR) is a global automation leader delivering solutions for the most demanding technology challenges. Headquartered in St. Louis, Missouri, Emerson is engineering the autonomous future, enabling customers to optimize operations and accelerate innovation. For more information, visit Emerson.com.Forward-Looking and Cautionary StatementsStatements in this press release that are not strictly historical may be "forward-looking" statements, which represent management's expectations, based on currently available information. Actual results, performance or achievements could differ materially from those expressed in any forward-looking statement. Any forward-looking statements in this press release speak only as of the date of this press release. Emerson undertakes no obligation to update any such statements to reflect new information or later developments. Examples of risks and uncertainties that may cause our actual results or performance to be materially different from those expressed or implied by forward looking statements include the scope, duration and ultimate impacts of the Russia-Ukraine and other global conflicts, as well as economic and currency conditions, market demand, pricing, protection of intellectual property, cybersecurity, tariffs, competitive and technological factors, inflation, among others, as set forth in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the SEC. The outlook contained herein represents the Company's expectation for its consolidated results, other than as noted herein.Emerson uses our Investor Relations website, https://ir.emerson.com, as a means of disclosing information which may be of interest or material to our investors and for complying with disclosure obligations under Regulation FD. Accordingly, investors should monitor our Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, webcasts and social media. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.Investors:Media:Doug AshbyJoseph Sala / Greg Klassen(314) 553-2197Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449(tables attached)

Table 1EMERSON AND SUBSIDIARIESCONSOLIDATED OPERATING RESULTS(AMOUNTS IN MILLIONS EXCEPT PER SHARE, UNAUDITED)

Quarter Ended Dec 31,
2024
2025

Net sales$           4,175
$           4,346Cost and expenses

     Cost of sales1,940
2,035     SG&A expenses1,224
1,242     Other deductions, net228
204     Interest expense, net8
90Earnings before income taxes775
775Income taxes182
169Net earnings593
606Less: Noncontrolling interests in subsidiaries8
1Net earnings common stockholders$              585
$              605

Diluted avg. shares outstanding571.1
564.1

Diluted earnings per share common stockholders

Diluted earnings per common share$             1.02
$             1.07

Quarter Ended Dec 31,
2024
2025Other deductions, net

Amortization of intangibles$              229
$              205Restructuring costs11
9Other(12)
(10)Total$              228
$              204

Table 2EMERSON AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(DOLLARS IN MILLIONS, UNAUDITED)

Sept 30, 2025
Dec 31, 2025Assets

     Cash and equivalents$           1,544
$           1,748     Receivables, net3,101
2,972     Inventories2,213
2,353     Other current assets1,725
1,770Total current assets8,583
8,843     Property, plant & equipment, net2,871
2,867     Goodwill18,193
18,182     Other intangibles9,458
9,205     Other2,859
2,842Total assets$         41,964
$         41,939

Liabilities and equity

     Short-term borrowings and current maturities of long-term debt$           4,797
$           5,832     Accounts payable1,384
1,339     Accrued expenses3,616
3,349Total current liabilities9,797
10,520     Long-term debt8,319
7,575     Other liabilities3,550
3,552Equity

     Common stockholders' equity 20,282
20,277     Noncontrolling interests in subsidiaries16
15Total equity20,298
20,292Total liabilities and equity$         41,964
$         41,939

Table 3EMERSON AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(DOLLARS IN MILLIONS, UNAUDITED)

Three Months Ended Dec 31,

2024
2025Operating activities

Net earnings
$              593
$              606Adjustments to reconcile net earnings to net cash provided by operating activities:

        Depreciation and amortization
383
359        Stock compensation
68
55        Changes in operating working capital
(154)
(357)        Other, net
(113)
36            Cash provided by operating activities
777
699

Investing activities

Capital expenditures
(83)
(97)Purchases of businesses, net of cash and equivalents acquired
(37)
—Other, net
(22)
(28)    Cash used in investing activities
(142)
(125)

Financing activities

Net increase (decrease) in short-term borrowings
2
(485)Proceeds from short-term borrowings greater than three months
—
3,473Payments of short-term borrowings greater than three months
—
(2,099)Payments of long-term debt
(2)
(587)Dividends paid
(301)
(312)Purchases of common stock
(899)
(250)Other, net
(91)
(104)    Cash used in financing activities
(1,291)
(364)

Effect of exchange rate changes on cash and equivalents
(98)
(6)Increase (decrease) in cash and equivalents
(754)
204Beginning cash and equivalents
3,588
1,544Ending cash and equivalents
$            2,834
$           1,748

Table 4EMERSON AND SUBSIDIARIESSEGMENT SALES AND EARNINGS(DOLLARS IN MILLIONS, UNAUDITED)
The following tables show results for the Company's segments on an adjusted segment EBITA basis and are intended to
supplement the Company's results of operations, including its segment earnings which are defined as earnings before
interest and taxes. The Company defines adjusted segment and total segment EBITA as segment earnings excluding
intangibles amortization expense, and restructuring and related expense. Adjusted segment and total segment EBITA,
and adjusted segment and total segment EBITA margin are measures used by management and may be useful for
investors to evaluate the Company's segments' operational performance.

Quarter Ended Dec 31,

2024
2025
Reported
Underlying
Sales

Control Systems & Software$           1,023
$           1,044
2 %
— %
Test & Measurement359
409
14 %
11 %
Software & Systems$           1,382
$           1,453
5 %
3 %

Sensors972
996
2 %
1 %
Final Control1,334
1,394
4 %
2 %
Intelligent Devices$           2,306
$           2,390
4 %
2 %

Safety & Productivity$              487
$              503
3 %
1 %

Total$           4,175
$           4,346
4 %
2 %
Sales Growth by Geography

Quarter Ended
Dec 31,

Americas3 %

Europe 3 %

Asia, Middle East & Africa— %

Table 4 cont.

Quarter Ended Dec 31,
Quarter Ended Dec 31,
2024
2025
As Reported
(GAAP)
Adjusted
EBITA
(Non-GAAP)
As
Reported
(GAAP)
Adjusted
EBITA
(Non-GAAP)Earnings

Control Systems & Software$          208
$          337
$          232
$          334 Margins20.3 %
33.0 %
22.2 %
31.9 %Test & Measurement(13)
91
14
121 Margins(3.6) %
25.5 %
3.6 %
29.7 %Software & Systems$          195
$          428
$          246
$          455 Margins14.1 %
31.1 %
17.0 %
31.3 %

Sensors285
296
266
282 Margins29.3 %
30.5 %
26.7 %
28.3 %Final Control305
341
331
361 Margins22.9 %
25.5 %
23.8 %
25.9 %Intelligent Devices$          590
$          637
$          597
$          643 Margins25.6 %
27.6 %
25.0 %
26.9 %

Safety & Productivity$            96
$          104
$            97
$          105 Margins19.7 %
21.3 %
19.2 %
20.9 %

Corporate items and interest expense, net:

Stock compensation(68)
(66)
(55)
(51)Unallocated pension and postretirement costs27
27
29
29Corporate and other(57)
(34)
(49)
(40)Interest expense, net(8)
—
(90)
—

Pretax Earnings / Adjusted EBITA$          775
$        1,096
$          775
$        1,141 Margins18.6 %
26.3 %
17.8 %
26.3 %

Supplemental Total Segment Earnings:

Adjusted Total Segment EBITA

$        1,169

$        1,203 Margins

28.0 %

27.7 %

Table 4 cont.

Quarter Ended Dec 31,
Quarter Ended Dec 31,

2024
2025

Amortization of Intangibles1
Restructuring and Related Costs2
Amortization of Intangibles1
Restructuring and Related Costs2
Control Systems & Software$                 127
$                     2
$                 101
$                     1
Test & Measurement105
(1)
107
—
Software & Systems$                 232
$                     1
$                 208
$                     1

Sensors10
1
11
5
Final Control29
7
28
2
Intelligent Devices$                   39
$                     8
$                   39
$                     7

Safety & Productivity$                     7
$                     1
$                     7
$                     1

Corporate—
3
—
2
Total$                 278
$                   13
$                 254
$                   11

1 Amortization of intangibles includes $49 reported in cost of sales for the three months ended December 31, 2024 and 2025.2 Restructuring and related costs includes $2 reported in selling, general and administrative expenses for the three months ended December 31, 2024 and 2025.

Quarter Ended Dec 31,Depreciation and Amortization2024
2025Control Systems & Software$              149
$              122Test & Measurement118
119Software & Systems267
241

Sensors31
33Final Control55
56Intelligent Devices86
89

Safety & Productivity19
19

Corporate11
10Total$              383
$              359

Table 5EMERSON AND SUBSIDIARIESADJUSTED CORPORATE AND OTHER SUPPLEMENTAL(DOLLARS IN MILLIONS, UNAUDITED)The following table shows the Company's stock compensation and corporate and other expenses on an adjusted basis.
The Company's definition of adjusted stock compensation excludes integration-related stock compensation expense. The
Company's definition of adjusted corporate and other excludes corporate restructuring and related costs, first year
purchase accounting related items and transaction fees, and certain gains, losses or impairments. This metric is useful for
reconciling from total adjusted segment EBITA to the Company's consolidated adjusted EBITA.

Quarter Ended Dec 31,

2024
2025
Stock compensation (GAAP)

$                  (68)
$                  (55)
    Integration-related stock compensation expense

2
4
Adjusted stock compensation (non-GAAP)

$                  (66)
$                  (51)

Quarter Ended Dec 31,

2024
2025
Corporate and other (GAAP)

$                  (57)
$                  (49)
Corporate restructuring and related costs

3
2
Acquisition / divestiture costs

20
7
Adjusted corporate and other (non-GAAP)

$                  (34)
$                  (40)

Table 6EMERSON AND SUBSIDIARIESADJUSTED EBITA & EPS SUPPLEMENTAL(AMOUNTS IN MILLIONS EXCEPT PER SHARE, UNAUDITED)
The following tables, which show results on an adjusted EBITA basis and diluted earnings per share on an adjusted basis,
are intended to supplement the Company's discussion of its results of operations herein. The Company defines adjusted
EBITA as earnings excluding interest expense, net, income taxes, intangibles amortization expense, restructuring
expense, first year purchase accounting related items and transaction fees, and certain gains, losses or impairments.
Adjusted earnings per share excludes intangibles amortization expense, restructuring expense, first year purchase
accounting related items and transaction-related costs, discrete taxes, and certain gains, losses or impairments. Adjusted
EBITA, adjusted EBITA margin, and adjusted earnings per share are measures used by management and may be useful
for investors to evaluate the Company's operational performance.

Quarter Ended Dec 31,
2024
2025Pretax earnings $             775
$             775Percent of sales18.6 %
17.8 %Interest expense, net8
90Amortization of intangibles278
254Restructuring and related costs13
11Acquisition/divestiture fees and related costs22
11Adjusted EBITA$          1,096
$          1,141Percent of sales26.3 %
26.3 %

Quarter Ended Dec 31,
2024
2025GAAP earnings per share$            1.02
$            1.07Amortization of intangibles0.31
0.35Restructuring and related costs0.02
0.02Acquisition/divestiture fees and related costs0.03
0.01Discrete taxes—
0.01Adjusted earnings per share$            1.38
$            1.46

Table 6 cont.
Quarter Ended December 31, 2025
Pretax
Earnings
Income
Taxes
Net
Earnings
Non-
ControllingInterests
Net
Earnings
Common
Stockholders
Diluted
Earnings
Per
ShareAs reported (GAAP)$         775
$         169
$         606
$             1
$            605
$        1.07Amortization of intangibles254159
195
—
195
0.35Restructuring and related costs1123
8
—
8
0.02Acquisition/divestiture fees and related costs11
2
9
—
9
0.01Discrete Taxes—
(5)
5
—
5
0.01Adjusted (non-GAAP)$      1,051
$         228
$         823
$             1
$            822
$        1.46Interest expense, net90

Adjusted EBITA (non-GAAP)$      1,141

1 Amortization of intangibles includes $49 reported in cost of sales.2 Restructuring and related costs includes $2 reported in selling, general and administrative expenses.
Reconciliations of Non-GAAP Financial Measures & Other
Table 8

Reconciliations of Non-GAAP measures with the most directly comparable GAAP measure (dollars in millions,
except per share amounts). See tables 4 through 7 for additional non-GAAP reconciliations.

2026 Q1 Underlying Sales ChangeReported(Favorable) /
Unfavorable FX(Acquisitions) /
DivestituresUnderlyingControl Systems & Software2 %(2) %— %— %Test & Measurement14 %(3) %— %11 %Software & Systems5 %(2) %— %3 %Sensors2 %(1) %— %1 %Final Control4 %(2) %— %2 %Intelligent Devices4 %(2) %— %2 %Safety and Productivity3 %(2) %— %1 %Emerson4 %(2) %— %2 % Underlying Growth Guidance2026 Q2
Guidance2026GuidanceReported (GAAP)3% - 4%~5.5%(Favorable) / Unfavorable FX~(2 pts)~(1.5 pts)(Acquisitions) / Divestitures--Underlying (non-GAAP)1% - 2%~4% 2025 Q1 Adjusted Segment EBITAEBITEBIT MarginAmortizationof IntangiblesRestructuring
and Related
CostsAdjusted
Segment
EBITAAdjusted
Segment
EBITA
MarginControl Systems & Software$               20820.3 %$               127$                     2$               33733.0 %Test & Measurement(13)(3.6) %105(1)9125.5 %Software & Systems$               19514.1 %$               232$                     1$               42831.1 %Sensors28529.3 %10129630.5 %Final Control30522.9 %29734125.5 %Intelligent Devices$               59025.6 %$                 39$                     8$               63727.6 %Safety & Productivity$                 9619.7 %$                    7$                     1$               10421.3 %
2026 Q1 Adjusted Segment EBITAEBITEBIT MarginAmortization
of
IntangiblesRestructuring
and Related
CostsAdjusted
Segment
EBITAAdjusted
Segment
EBITA
MarginControl Systems & Software$               23222.2 %$               101$                     1$               33431.9 %Test & Measurement143.6 %107—12129.7 %Software & Systems$               24617.0 %$               208$                     1$               45531.3 %Sensors26626.7 %11528228.3 %Final Control33123.8 %28236125.9 %Intelligent Devices$               59725.0 %$                 39$                     7$               64326.9 %Safety & Productivity$                 9719.2 %$                    7$                     1$               10520.9 %

Total Adjusted Segment EBITA
2025 Q12026 Q1Pretax earnings (GAAP)
$                 775$                 775Margin
18.6 %17.8 %Corporate items and interest expense, net
106165Amortization of intangibles
278254Restructuring and related costs
109Adjusted segment EBITA (non-GAAP)
$              1,169$              1,203Margin
28.0 %27.7 % Free Cash Flow
2025 Q12026 Q1
2026E($ in billions)
Operating cash flow (GAAP)
$                 777$                 699
$4.0 - $4.1
Capital expenditures
(83)(97)
~(0.45)
Free cash flow (non-GAAP)
$                 694$                 602
$3.5 - $3.6

Note 1: Underlying sales and orders exclude the impact of currency translation and significant acquisitions and divestitures.Note 2: All fiscal year 2026E figures are approximate, except where range is given.

View original content to download multimedia:https://www.prnewswire.com/news-releases/emerson-reports-first-quarter-2026-results-updates-2026-outlook-302677917.htmlSOURCE Emerson

Original: Emerson Reports First Quarter 2026 Results; Updates 2026 Outlook